A rare malaria victory

| 2 min read

I've been looking into how global health programs evaluate the effects of their interventions for a story that will appear in our March issue. Public health experts have told me again and again that too little attention has been paid to evaluation across the board. This morning (Feb.1), both linkurl:__The Washington Post__;http://www.washingtonpost.com/wp-dyn/content/article/2008/01/31/AR2008013101943.html?wpisrc=newsletter and linkurl:__The New York Times__;http://www.nytimes.com/2008/02/01/health/01malaria.html?_r=1&ref=world&oref=slogin reported on a study by the World Health Organization that seems to address this issue. The study looked at how well distributing of insecticide-treated bed nets and linkurl:artemisinin,;http://www.the-scientist.com/article/display/36878/ the newest anti-malarial drug, affected rates of child malaria deaths in Ethiopia, Ghana, Rwanda, and Zambia. The team found that children's deaths from malaria have dropped by about 50 percent in Ethiopia, where 20 million nets were distributed over two years, and by more than 60 percent in Rwanda, where two million nets were distributed over two months in 2006. The 33 percent decline in malaria deaths among Zambian children would have been greater if supplies of nets and drugs hadn't run out in many areas, the report suggests. Data from Ghana, though, seemed a bit more puzzling. Ghana received little funding from the Global Fund, which heavily subsidized programs in the other three countries. This meant that Ghana was not able to buy many bed nets and had to charge patients for drugs. But still, the country saw a 34 percent decrease in child malaria deaths. The study got its data from local hospitals. It's an improvement over programs that don't do any follow-up monitoring of their programs at all. But I can't help but wonder what additional insights could have been gained from more thorough data collection and analysis. Counting deaths in malaria-stricken children is something, but tracking malaria infection rates in a wider segment of the Ghanaian population might have provided other explanations for the decrease in deaths, such as vector population declines or decreases in transmission rates. In other malaria news (that happens to intersect my fascination with linkurl:chimpanzees),;http://www.the-scientist.com/article/display/53392/ clinical trials on a malaria linkurl:vaccine;http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html?in_article_id=511600&in_page_id=1774 based on a chimp virus have begun in the UK.

A rare malaria victory

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

Bunsen Burners and Bad Hair Days

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Taking the Guesswork Out of Quality Control Standards

PFAS: The Forever Chemicals

Unlocking the Unattainable in Gene Construction

Comparing Analytical Solutions for High-Throughput Drug Discovery

Products

Product News

Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China

Thermo Scientific™ Centrifuges with GreenCool Technology

Singleron Biotechnologies and Hamilton Bonaduz AG Announce the Launch of Tensor to Advance Single Cell Sequencing Automation

Zymo Research Launches Research Grant to Empower Mapping the RNome